| Patient Safety |
1 |
1 |
| Adverse Effects |
0 |
0.99 |
| Depression |
0 |
0.76 |
| Food and Drug Administration (FDA) |
0 |
0.98 |
| Suicide |
0 |
0.32 |
| Hair |
0 |
0.28 |
| Sexual Dysfunction |
0 |
0.2 |
| Generics |
0 |
0.12 |
| HIV Infection |
0 |
0.11 |
| Benign Prostatic Hyperplasia |
0 |
0.1 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Brain |
0 |
0.08 |
| Expert Testimony |
0 |
0.08 |
| New York |
0 |
0.08 |
| Prostate Cancer |
0 |
0.08 |
| Steroids |
0 |
0.08 |
| 5-Alpha Reductase Inhibitors |
0 |
0.06 |
| Alopecia |
0 |
0.04 |
| Anxiety |
0 |
0.04 |
| Anxiety Disorder |
0 |
0.04 |
| Central Nervous System |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Fellowship |
0 |
0.04 |
| Gonad |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Health Care Quality, Access, and Evaluation |
0 |
0.04 |
| Hospital |
0 |
0.04 |
| Mental Illness |
0 |
0.95 |
| New Jersey |
0 |
0.04 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.04 |
| Private Practice |
0 |
0.04 |
| Prostate |
0 |
0.04 |
| Sleep |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Statistics |
0 |
0.04 |
| Stress |
0 |
0.04 |
| Surgery |
0 |
0.04 |
| Telehealth and Telemedicine |
0 |
0.04 |
| UK Site Content |
0 |
0.04 |